HRMY, US4131971040

Harmony Biosciences stock fell 1.40 percent on October 6

Published on 10/07/2026 at 03:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harmony Biosciences stock is backed by USD 261.3 million in Q2 WAKIX revenue, up 30 percent year over year. An 11-analyst Hold consensus carries a USD 47.44 target.

HRMY, US4131971040, Illustration mit AI erstellt.

Harmony Biosciences (ISIN US4131971040) was last at USD 39.36 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 1.40 percent for the session. Management's scheduled meetings with Oppenheimer in Denver on October 6 and Houston on October 7 put the company's pipeline and WAKIX franchise back before analysts, according to Markets Insider.

Q2 revenue sets the base

Harmony's second-quarter 2026 revenue was USD 261.28 million, while net income reached USD 75.43 million and diluted EPS was USD 1.28. The figures came from the June 30, 2026 quarter and give the current valuation a stronger operating anchor than the daily price move alone.

The company reported WAKIX net revenue of USD 261.3 million for Q2 2026, up 30 percent from the year-earlier period, and reiterated 2026 WAKIX revenue guidance of USD 1.0 billion to USD 1.04 billion, according to Harmony Biosciences.

Pipeline broadens the story

Harmony is also developing HBS-301 in two Phase 3 trials, ONSTRIDE-1 for narcolepsy and ONSTRIDE-2 for idiopathic hypersomnia. The company presented the program at the 17th European Narcolepsy Days on October 2 and October 3, 2026, according to BioSpace.

That pipeline matters because WAKIX remains the company's commercial foundation, while late-stage development adds potential uses beyond adult narcolepsy. The tradeoff is execution: clinical progress must complement the existing product's revenue growth rather than merely offset concentration risk.

Consensus stays above the price

The consensus rating is Hold from 11 analysts, with an average price target of USD 47.44, a high target of USD 70.00 and a low target of USD 28.00, according to MarketBeat. The average target lies 20.5 percent above the October 6 price of USD 39.36, leaving the analyst view more constructive than the neutral rating label suggests.

HRMY stays below its yearly high

At USD 39.36, Harmony Biosciences stock stood 9.5 percent below its 52-week high of USD 43.49 and above its 52-week low of USD 25.52 on October 6, 2026. Market capitalization was USD 2.3 billion, with 507,272 shares traded.